Published in Pharmacol Rep on July 15, 2010
Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev (2012) 1.82
Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J Lipid Res (2012) 1.12
Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2011) 1.00
Method for Sorting and Pairwise Selection of Nanobodies for the Development of Highly Sensitive Sandwich Immunoassays. Anal Chem (2015) 0.78
Hypoxemia, oxygen content, and the regulation of cerebral blood flow. Am J Physiol Regul Integr Comp Physiol (2015) 0.78
Blood cells: an historical account of the roles of purinergic signalling. Purinergic Signal (2015) 0.78
P2X and P2Y receptor signaling in red blood cells. Front Mol Biosci (2015) 0.75
Enzymatic and Free Radical Formation of Cis- and Trans- Epoxyeicosatrienoic Acids In Vitro and In Vivo. Free Radic Biol Med (2017) 0.75
Receptors for purines and pyrimidines. Pharmacol Rev (1998) 13.92
Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (1999) 4.47
Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A (2005) 4.07
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol (2004) 3.43
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol (2005) 3.38
Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res (2004) 3.33
Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem (2000) 3.15
Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res (1992) 2.86
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab (2007) 2.41
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A (2005) 2.25
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol (2005) 2.10
The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A (2005) 2.10
Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem (1993) 2.03
The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol (2007) 1.99
Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem (2001) 1.97
Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension (2007) 1.83
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2005) 1.76
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet (2006) 1.74
Flow control among microvessels coordinated by intercellular conduction. Science (1986) 1.72
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2007) 1.60
New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci (2000) 1.52
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys (2007) 1.38
Stimulation of rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol (2007) 1.34
Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol (2004) 1.34
Red not dead: signaling in and from erythrocytes. Trends Endocrinol Metab (2007) 1.29
Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol (2000) 1.21
Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol (1999) 1.20
Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther (2005) 1.17
Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid. Biochem Biophys Res Commun (1982) 1.16
Plasma ATP during exercise: possible role in regulation of coronary blood flow. Am J Physiol Heart Circ Physiol (2004) 1.15
Analysis of epoxyeicosatrienoic and monohydroxyeicosatetraenoic acids esterified to phospholipids in human red blood cells by electrospray tandem mass spectrometry. J Mass Spectrom (1997) 1.14
Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem (1992) 1.12
Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension (1995) 1.04
Effect of diabetes and starvation on the activity of rat liver epoxide hydrolases, glutathione S-transferases and peroxisomal beta-oxidation. Biochem Pharmacol (1989) 1.03
Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver. Science (1980) 1.00
Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells. J Biol Chem (2004) 0.98
Failure to upregulate the adenosine2A receptor-epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats. Am J Physiol Renal Physiol (2008) 0.95
Red blood cells: reservoirs of cis- and trans-epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat (2005) 0.94
Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. J Pharmacol Exp Ther (1998) 0.92
Eicosanoid imbalance in the NOD mouse is related to a dysregulation in soluble epoxide hydrolase and 15-PGDH expression. Ann N Y Acad Sci (2006) 0.91
Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol (2008) 0.90
Involvement of eicosanoids in release of oxytocin and vasopressin from the neural lobe of the rat pituitary. Endocrinology (1985) 0.88
Berne's adenosine hypothesis of coronary blood flow control. Am J Physiol Heart Circ Physiol (2004) 0.87
A novel pool of rat liver inositol and ethanolamine phospholipids contains epoxyeicosatrienoic acids (EETs). Biochem Biophys Res Commun (1987) 0.86
Substrate specificity of the monooxygenase activity of hemoglobin. Mol Pharmacol (1984) 0.79
Purification and characterization of a cytosolic, 42-kDa and Ca2+-dependent phospholipase A2 from bovine red blood cells: its involvement in Ca2+-dependent release of arachidonic acid from mammalian red blood cells. J Biol Chem (2002) 0.78
Novel Role of Soluble Epoxide Hydrolase in Regulating Cholesterol in Mammalian Cells. Open Drug Metab J (2007) 0.78
Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol (2007) 2.68
Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia (2002) 1.82
Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am J Physiol Renal Physiol (2006) 1.16
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension (2008) 1.12
Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat. J Neurotrauma (2006) 1.10
Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol (2005) 1.05
Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat (2003) 1.03
Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. Am J Physiol Heart Circ Physiol (2006) 1.01
Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells. J Pharmacol Exp Ther (2008) 0.99
Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells. J Biol Chem (2004) 0.98
Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy (2008) 0.98
Characterization of a long-term rat mTAL cell line. Am J Physiol Renal Physiol (2007) 0.97
Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury. Oxid Med Cell Longev (2010) 0.97
The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol (2003) 0.97
Failure to upregulate the adenosine2A receptor-epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats. Am J Physiol Renal Physiol (2008) 0.95
Red blood cells: reservoirs of cis- and trans-epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat (2005) 0.94
5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. Hypertension (2003) 0.94
Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am J Physiol Renal Physiol (2002) 0.94
Exaggerated response to adenosine in kidneys from high salt-fed rats: role of epoxyeicosatrienoic acids. Am J Physiol Renal Physiol (2005) 0.92
Pioglitazone: effect on CYP3A4 activity. J Clin Pharmacol (2002) 0.92
Calcium-sensing receptor-mediated TNF production in medullary thick ascending limb cells. Am J Physiol Renal Physiol (2002) 0.91
Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther (2003) 0.91
A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Med (2008) 0.90
Renal arterial 20-hydroxyeicosatetraenoic acid levels: regulation by cyclooxygenase. Am J Physiol Renal Physiol (2002) 0.90
Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol (2006) 0.90
CaR activation increases TNF production by mTAL cells via a Gi-dependent mechanism. Am J Physiol Renal Physiol (2007) 0.89
NFAT regulates calcium-sensing receptor-mediated TNF production. Am J Physiol Renal Physiol (2005) 0.89
Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet (2014) 0.88
Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury. Behav Brain Res (2011) 0.87
A comparison of the effects of nicotinamide and progesterone on functional recovery of cognitive behavior following cortical contusion injury in the rat. J Neurotrauma (2012) 0.87
Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia (2007) 0.86
The red blood cell participates in regulation of the circulation by producing and releasing epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat (2011) 0.85
Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos (2006) 0.85
Is ethnicity associated with morphine's side effects in children? Morphine pharmacokinetics, analgesic response, and side effects in children having tonsillectomy. Paediatr Anaesth (2012) 0.84
Bradykinin regulates cyclooxygenase-2 in rat renal thick ascending limb cells. Hypertension (2004) 0.83
Calcium-sensing receptor signaling pathways in medullary thick ascending limb cells mediate COX-2-derived PGE2 production: functional significance. Am J Physiol Renal Physiol (2008) 0.82
Maternal and fetal epoxyeicosatrienoic acids in normotensive and preeclamptic pregnancies. Am J Hypertens (2012) 0.82
Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. Paediatr Anaesth (2010) 0.82
Voltage-dependent block of N-methyl-D-aspartate receptors by the novel anticonvulsant dibenzylamine, a bioactive constituent of L-(+)-beta-hydroxybutyrate. Epilepsia (2003) 0.81
Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother (2007) 0.81
Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anesth Analg (2007) 0.81
Renal COX-2, cytokines and 20-HETE: tubular and vascular mechanisms. Curr Pharm Des (2004) 0.80
Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet (2002) 0.79
Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 0.79
TNFalpha regulates renal COX-2 in the rat thick ascending limb (TAL). Thromb Res (2003) 0.79
Products of arachidonic acid metabolism. Methods Mol Med (2003) 0.79
Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol). Clin Pharmacokinet (2014) 0.78
11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat (2011) 0.78
Digoxin therapy and the risk of primary cardiac arrest in patients with congestive heart failure: effect of mild-moderate renal impairment. J Clin Epidemiol (2003) 0.78
Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med (2002) 0.77
Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression. Brain Res Mol Brain Res (2005) 0.77
Magnesium for neuroprotection after traumatic brain injury. Lancet Neurol (2007) 0.77
Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration. Antimicrob Agents Chemother (2009) 0.77
Comparison of the effect of minocycline and simvastatin on functional recovery and gene expression in a rat traumatic brain injury model. J Neurotrauma (2014) 0.77
20-HETE contributes to ischemia-induced angiogenesis. Vascul Pharmacol (2016) 0.76
Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum. J Clin Pharmacol (2010) 0.75
Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: what's the problem with generic antiepileptic drugs? A call to action. Neurology (2007) 0.75
Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide. Ther Clin Risk Manag (2009) 0.75
Purinoceptors in renal microvessels: adenosine-activated and cytochrome P450 monooxygenase-derived arachidonate metabolites. Pharmacol Rep (2005) 0.75
Regulation of renal microvascular 20-hydroxyeicosatetraenoic acid (20-HETE) levels. Adv Exp Med Biol (2003) 0.75
Peter Ramwell: a remembrance. Prostaglandins Other Lipid Mediat (2011) 0.75
Cytochrome P450 arachidonic acid metabolites modulate renal tubular function. Adv Exp Med Biol (2003) 0.75